Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors - Dataset (ID:20233)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2586 | Ruxolitinib | 0.3 | uM | IL-6 | 100 | ug/mL | 3 | b-NGF | 69.0 | 56 | |
N2586 | Tofacitinib | 0.3 | uM | IL-6 | 100 | ug/mL | 3 | b-NGF | 48.0 | 58 | |
N2586 | IKK16 | 2.0 | uM | IL-6 | 100 | ug/mL | 3 | b-NGF | 52.0 | 64 | |
N2586 | Sigma A6730 | 3.0 | uM | 3 | b-NGF | 66.0 | 55 | ||||
RA2159 | IL-1 alpha | 100 | ng/mL | 3 | b-NGF | 75.0 | 68 | ||||
RA2159 | PD184352 | 0.1 | uM | IL-1 alpha | 100 | ng/mL | 3 | b-NGF | 83.5 | 58 | |
RA2159 | Lestaurtinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | b-NGF | 80.0 | 77 | |
RA2159 | Ruxolitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | b-NGF | 109.0 | 75 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | b-NGF | 109.5 | 48 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | b-NGF | 34.5 | 60 | |
RA2159 | PI103 | 0.1 | uM | 3 | b-NGF | 33.0 | 43 | ||||
N2586 | IL-1 alpha | 100 | ng/mL | 3 | b-NGF | 237.0 | 66 | ||||
N2586 | PD184352 | 0.1 | uM | IL-1 alpha | 100 | ng/mL | 3 | b-NGF | 293.5 | 40 | |
N2586 | Lestaurtinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | b-NGF | 255.5 | 54 | |
N2586 | Ruxolitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | b-NGF | 315.0 | 64 | |
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | b-NGF | 61.0 | 63 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | b-NGF | 100.5 | 60 | |
N2586 | PI103 | 0.1 | uM | 3 | b-NGF | 50.0 | 65 | ||||
0 | b-NGF | 7.0 | 56 | ||||||||
RA2159 | TNF-a | 100 | ng/mL | 3 | b-NGF | 191.0 | 55 | ||||
RA2159 | PD184352 | 0.1 | uM | TNF-a | 100 | ng/mL | 3 | b-NGF | 127.0 | 53 | |
RA2159 | Lestaurtinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | b-NGF | 107.0 | 80 | |
RA2159 | Ruxolitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | b-NGF | 120.0 | 39 | |
RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | b-NGF | 106.0 | 74 | |
RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | b-NGF | 58.0 | 60 |